Advertisement

Picture Consultech GmbH Secure Funding with RnD Grants v7 650x100px
Organisation › Details

3PBiovian, Boston Office

Biovian and 3P Biopharmaceuticals join forces to create 3PBIOVIAN, a leading pan-European biologics CDMO > Biovian and 3P Biopharmaceuticals (“3P”), two leading biologics Contract Development and Manufacturing Organizations (CDMOs), announced today their combination to establish a new pan-European leader in their field. > Backed by their common shareholder, Keensight Capital, one of the leading private equity funds dedicated to pan-European Growth Buyout[1] investments, the combination of Biovian and 3P further extends the group’s value proposition to address complex customer needs across the entire development cycle. The combined Group, named 3PBIOVIAN, will offer unparalleled end-to-end development and manufacturing services for all protein expression systems and viral vectors, both for Drug Substance and Drug Product, from preclinical to clinical development and commercial phases. Leveraging a joint 40-year track record, expertise, capabilities, and financial strength, the Group will position itself as a leading pan-European independent biologics CDMO, aiming to spearhead the development of drugs tackling patients’ unmet clinical needs. Through this combination, the Group will become one of the main independent European bio-CDMOs, with gross sales above €75m. Biovian and 3P Biopharmaceuticals have each delivered consistent double-digit growth historically, and this organic growth will underpin the development of the combined business going forward. With over 500 professionals and operating across manufacturing facilities of 15,800 square meters, the group is now ideally positioned to effectively address the growing demands of the market. 3PBIOVIAN will leverage its manufacturing sites in Pamplona-Noáin (Spain) and Turku (Finland) as well as its commercial office in Boston, MA (United States) to address an extensive array of customer needs. Its end-to-end offering will span across multiple platforms (microbial and mammalian expression, adenoviruses, adeno-associated viruses, cell therapy and plasmids) and offers enhanced production scale flexibility via a diverse range of bioreactor sizes. This comprehensive set of services will target a global base of biopharma clients looking for scientific expertise, premium quality, and outstanding customer service. 3PBIOVIAN will continue to be led by its team of seasoned professionals in the biologics industry, driving its growth ambitions going forward. Dámaso Molero Sánchez (former 3P CEO) will serve as Group CEO supported by Deputy CEO Antti Nieminen (former Biovian CEO), Heidi Suuronen as CFO and Elena Erroba as CCO (Chief Commercial Officer). *

 

Period Start 2024-02-01 existent
  Group 3PBiovian (Group) (3P Pharmaceuticals + Biovian owned by PE firm Keensight Capital)
Product Industry contract manufacturing (biologicals)
     
Region Region Boston, MA
  Country United States (USA)
  Street 53 State Street
Suites 503 + 504
  City 02109 Boston, MA
    Address record changed: 2026-09-30
     
Basic data Employees D: 101 to 500 (2019-07-23)
     
    * Document for »About Section«: 3P Biopharmaceuticals S.L.U.. (2/1/24). "Press Release: Biovian and 3P Biopharmaceuticals Join Forces to Create 3PBiovian, a Leading Pan-European Biologics CDMO".
     
   
Record changed: 2026-09-30

Advertisement

Picture Flex Databases Software for Life Sciences LSE 650x200px

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture Flex CTMS with Built-in eTMF LSE 650x300px




» top